Introduction: Non-Hodgkin lymphomas (NHL) comprise a heterogeneous group of hematological malignancies, primarily originating from B-cells. Among its subtypes, diffuse lymphomas (ICD-10: C83), cutaneous and peripheral T-cell lymphomas (ICD-10: C84), and other and unspecified types of NHL (ICD-10: C85) stand out. These cancers exhibit wide clinical and prognostic variability, demanding ongoing epidemiological surveillance. In Brazil, according to data from the National Cancer Institute (INCA, 2023), NHLs are among the ten most frequent cancer types in both men and women. Given the geographical, socioeconomic, and infrastructural particularities of the Northern Region, epidemiological analyses are essential to guide public policies and local healthcare interventions. Objectives: To analyze mortality data related to non-Hodgkin lymphomas in Northern Brazil between 2019 and 2023, focusing on temporal distribution, sex, age group, and geographic location. Methodology: This is a descriptive, retrospective epidemiological study based on data from the Mortality Information System (SIM), accessed through the TABNET/DATASUS platform. The analysis included deaths recorded from 2019 to 2023 with underlying causes classified under ICD-10 codes C83, C84, and C85. Variables considered were year of death, sex, age group, and state of residence. Records with incomplete information or from outside the Northern region were excluded. Data was organized and analyzed using Microsoft Excel, with calculations of absolute and relative frequencies, proportional mortality rates (per 100,000), and identification of temporal trends and geographic patterns. Results: A total of 831 deaths from non-Hodgkin lymphomas were recorded in Northern Brazil between 2019 and 2023, corresponding to approximately 1.7 deaths per 100,000 inhabitants per year. The state of Pará reported the highest number of deaths (n = 386; 46.44%), followed by Amazonas (n = 153; 18.40%) and Rondônia (n = 95; 11.43%). Most deaths occurred among males (59.6%) and individuals aged over 60 years (43.8%). Among NHL subtypes, C85 (other and unspecified types) was the most prevalent (n = 547; 65.8%), followed by C83 (diffuse NHL) with 231 deaths (27.8%), and C84 (cutaneous and peripheral T-cell lymphomas) with 53 deaths (6.4%). A fluctuating mortality trend was observed, with a slight decline in 2022 (147 deaths) and a peak in 2023 (183 deaths), the highest in the study period. Although states such as Roraima (36 deaths), Amapá (38 deaths), and Acre (36 deaths) reported lower absolute numbers, their proportional mortality rates suggest a significant impact, especially considering their smaller populations. Conclusion: The study reveals persistently high mortality rates from NHL in Northern Brazil, with a concentration of cases in the states of Pará and Amazonas, predominance among elderly males, and a higher incidence of the C85 subtype. The heterogeneity across states indicates marked regional disparities in access to diagnosis and oncological treatment. Temporal fluctuations and geographic discrepancies underscore the need for region-specific strategies to strengthen and modernize cancer care networks, with an emphasis on early diagnosis, access to advanced therapies such as CAR-T cell treatment, and continuous support for epidemiological surveillance. Further investigations are essential to understand the barriers faced by the Northern Brazilian population in accessing cancer care and to propose more equitable healthcare solutions.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
